<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587778</url>
  </required_header>
  <id_info>
    <org_study_id>v1.7_21.02.2020</org_study_id>
    <nct_id>NCT04587778</nct_id>
  </id_info>
  <brief_title>Imaging Neural Correlates of Ketamine Using PET/MR</brief_title>
  <acronym>RSKet</acronym>
  <official_title>Imaging Neural Correlates of Antidepressant Action of Ketamine Stereoisomers Using Pharmacological PET/MR Imaging and Metabolite Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic&#xD;
      differences between racemic ketamine and esketamine using functional fluorodeoxyglucose&#xD;
      ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MR)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cerebral metabolic rate of glucose (CMRGlu)</measure>
    <time_frame>during PETMR/during 45 minutes of infusion</time_frame>
    <description>Change in CMRGlu between each PET/MR scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cerebral blood flow (CBF)</measure>
    <time_frame>during PETMR/during 45 minutes of infusion</time_frame>
    <description>Change in CMRGlu between each PET/MR scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale</measure>
    <time_frame>one hour after infusion to baseline</time_frame>
    <description>Minimum: 30, Maximum: 210; higher score indicates worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Psychiatric Rating Scale</measure>
    <time_frame>one hour after infusion to baseline</time_frame>
    <description>Minimum: 18, Maximum: 126; higher score indicates worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician Administered Dissociative States Scale</measure>
    <time_frame>one hour after infusion to baseline</time_frame>
    <description>Minimum: 0, Maximum: 92; higher score indicates worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Esketamine ((S)-Ketamine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.&#xD;
In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Racemic ketamine ((R,S)-Ketamine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.&#xD;
In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Esketamine ((S)-Ketamine)</arm_group_label>
    <arm_group_label>Racemic ketamine ((R,S)-Ketamine)</arm_group_label>
    <other_name>Racemic ketamine (R, S)-Ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Esketamine ((S)-Ketamine)</arm_group_label>
    <arm_group_label>Racemic ketamine ((R,S)-Ketamine)</arm_group_label>
    <other_name>(S)-Ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Esketamine ((S)-Ketamine)</arm_group_label>
    <arm_group_label>Racemic ketamine ((R,S)-Ketamine)</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General health based on medical history, physical examination and structured clinical&#xD;
             interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)&#xD;
             (SCID)&#xD;
&#xD;
          -  Age 18 to 55 years&#xD;
&#xD;
          -  Right-handedness (due to potential lateralization effects of lefthanded subjects)&#xD;
&#xD;
          -  Willingness and competence to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of psychiatric or neurological disease&#xD;
&#xD;
          -  Current medical illness requiring treatment&#xD;
&#xD;
          -  Pregnancy or current breastfeeding&#xD;
&#xD;
          -  Current or former substance abuse&#xD;
&#xD;
          -  Diagnosis of an Axis-1 psychotic disorder in a first-degree relative&#xD;
&#xD;
          -  Any contraindication for MRI (e.g., MR incompatible implants, etc.) including dental&#xD;
             implants causing signal artifacts&#xD;
&#xD;
          -  For subjects participating in earlier studies using ionizing radiation, the total&#xD;
             radiation exposure of 30 millisievert (mSv) over the last 10 years must not be&#xD;
             exceeded, as specified in the Austrian legislation on radiation protection&#xD;
             (www.ris.bka.gv.at). Accordingly, body weight &gt;100kg is an exclusion criterion (5.1&#xD;
             Megabequerel (MBq)/kg * 100kg * 0.019 mSv/MBq* 0.885 = 8.58 mSv per scan, the factor&#xD;
             0.885 is considered due to continuous radioligand infusion, see PET scanning).&#xD;
&#xD;
          -  Failure to comply with the study protocol or to follow the instruction of the&#xD;
             investigating team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

